Sirio Pharma Launches SirioSure Quality Assurance Initiative for Nutrition Products
Jan 16, 2025
Sirio Pharma Launches SirioSure Quality Assurance Initiative for Nutrition Products
Comprehensive QA/QC program runs full product lifespan, from ingredient sourcing and data-informed development through mass manufacture, final inspection and commercialization.
City of Industry, CA – Sirio Pharma (Sirio), a leading global nutraceutical contract development and manufacturing organization (CDMO), has launched a comprehensive quality control initiative providing efficacy and effectiveness assurances for nutrition product brand owners and their customers. The company’s SirioSure program encompasses the extensive, often pharma-grade QA/QC efforts Sirio Pharma provides for its customers, allowing for increased confidence in promoted ingredient levels, label claims, and overall product quality.
Leaning into the company’s history as a legacy pharmaceuticals manufacturer, SirioSure brings together a variety of sweeping quality assurance and quality control activities. Elements such as thorough supplier vetting, expertise-driven formulation development, detailed ingredient shelf-life analyses and production line data collection seamlessly combine to help ensure long-term product efficacy. Meanwhile, sophisticated inspection and testing equipment, optimized facility floorplans, and system-wide, unit-level traceability provide transparency and tight process oversight.
For nutrition companies seeking development and manufacturing partners, Sirio Pharma’s holistic QA/QC efforts amount to a welcome outlier. Per an alarming recent field study whose results were published in JAMA Network Open, a mere 11% of nearly 60 tested supplements provided the amount of key ingredients listed on their labels. The revelation sparked a round of negative press in prominent outlets, including Science News.
Countering this stubborn nutrition industry narrative, Sirio Pharma’s elevated approach to QA/QC comprises an integrated mix of manpower and machinery. The company’s team of experienced quality management professionals provides strong support for front-end research and development, ensuring that the manufacturing process is exacting right from conception. Further downstream, robust inspection capabilities include modern laboratories and state-of-the-art instruments and equipment. System-wide digitization and regular process reviews and reexaminations create further quality assurance guardrails.
Notably, SirioSure is a living, breathing QA/QC initiative. Most recently, Sirio Pharma announced plans to procure a gas chromatography-mass spectrometry (GC-MS/MS) system, which will further broaden and deepen the company’s foreign particle detection and analysis. Among other capabilities, the module will enhance Sirio Pharma’s ability to detect and deter pesticide residues, a point of ongoing industry-wide concern.
“Since Sirio was originally a pharmaceutical company, we’ve always brought a pharma-grade approach to quality assurance and control,” said Sara Lesina, General Manager Sirio Europe & Americas. “We pride ourselves on developing and manufacturing products that include what their labels say they include – and perform how their brand owners promise they’ll perform. To accomplish this amid an ever-expanding global marketplace, our SirioSure quality management protocols are constantly evolving to meet and exceed various regional regulations and customer requirements.”
“At Sirio Pharma, our commitment to providing safe and reliable products drives us to continuously pursue higher quality,” said Ryan Li, Head of Quality at Sirio Pharma. “We are harnessing the power of technological advancements, from advanced process monitoring and automated inspection systems to AI and other digital tools, to enhance our quality standards, ensure food safety, and contribute to the advancement of global health.”
###
About SIRIO Pharma
Established in 1993, SIRIO Pharma Co., Ltd (SIRIO) is a leading global nutraceutical contract development and manufacturing organization (CDMO) with extensive expertise in an array of delivery formats, including gummies, softgels, capsules, tablets, powders, functional beverages, probiotics, and other innovative dosage forms. Dedicated to excellence in product development and manufacturing. SIRIO operates multiple state-of-the-art manufacturing sites across the United States, Germany and China.
In 2023, SIRIO acquired Best Formulations, further solidifying its position as a premier global nutraceutical CDMO, and significantly enhancing its manufacturing capabilities and capacity – with a notable focus on bolstering its presence in North America. For more information, visit www.siriopharma.com.
